We recently sat down with Jonathan Cherry, Global Project Leader, to learn more about PTC’s ferroptosis and inflammation scientific platform and how it relates to #FriedreichAtaxia (FA). Read more: bit.ly/44KxkBa

Today we announced that the EC has decided not to adopt the CHMP's negative opinion of Translarna™ (ataluren) and has returned the opinion to the CHMP for re-evaluation. Read more: bit.ly/3V4G1TE

We’re proud to support this year’s CureDuchenne FUTURES National Conference in Orlando, FL from May 23-26 and engage with the #DMD community. See you at booth #12! Learn more: bit.ly/3WNiKXF

Today we announced that the sepiapterin MAA for PKU has been validated and accepted for review by the EMA. Read more: bit.ly/3WYlX6Q

For #HuntingtonsDisease (#HD) awareness month, Jenna Woodard shares how her anger and fear towards her diagnosis changed to positivity and a determination to help others—through her connection with incredible medical staff and the beautiful HD community. rarerevolutionmagazine.com/huntingtons-di…

PTC Therapeutics announced that we will present a company overview at an upcoming investor conference. Read more: bit.ly/4aDLxRF

A reminder that PTC will be presenting a company overview at William Blair's 44th Annual Growth Stock Conference today, June 4. Learn more: bit.ly/4aDLxRF

As #ALSAwarenessMonth comes to an end in the U.S, we know the work doesn’t stop here. We applaud the Live Like Lou Foundation and many others in the community for their continued efforts. Through collaboration, compassion, and partnership, we can go further together.

Today we shared interim 12-month results from the Phase 2 PIVOT-HD study of PTC518 in Huntington’s disease (HD) patients. Read more: bit.ly/3KO3W3T

Early diagnosis of #ALS can be challenging. On this global #ALSAwarenessDay, learn more about the signs and symptoms.

Today we announced that the company will host a webcast to report its second quarter 2024 financial results on Thursday, August 8. Read more: bit.ly/4cTQiZq

Today we announced the submission of the sepiapterin NDA to the U.S. FDA for the treatment of pediatric and adult patients with PKU. Read more: bit.ly/3A0MMOd

Today, our leaders provided a corporate update and reported our second quarter 2024 financial results. Read more: bit.ly/3yErRQA

In a recent article for pharmaphorum, PTC's Edouard Dumont Saint Priest discusses the importance of intercultural intelligence to help pharma and biotech companies grow effectively in emerging markets worldwide. Read more: bit.ly/3YGDOzX

Today, PTC announced that the company will present a company overview at upcoming investor conferences. Learn more: bit.ly/3yMi3Ex

As we approach World Duchenne Awareness Day on Sept. 7, we are honoring this year’s theme of “Raise Your Voice for Duchenne” by highlighting remarkable individuals from our #DuchenneCAN series who are doing just that. #WDAD2024 #DuchenneMuscularDystrophy

We’re proud to be attending #SSIEM 2024 in Porto, Portugal. We invite healthcare professionals attending the conference to join us for our sponsored symposium sessions focused on #AADCdeficiency and #PKU. #ExploringNewHorizons #Porto

Join us at #SSIEM 2024 where we'll be discussing #AADCdeficiency and #PKU. Learn more about our poster presentations below and visit us at booth #S12/S13! #ExploringNewHorizons #Porto

On 9/7, we honor the #WDAD2024 theme of “raise your voice for Duchenne” by highlighting remarkable individuals from the #Duchenne community who are raising awareness and inspiration. As we near World Duchenne Awareness Day, we're proud to share these incredible stories.

PTC supported a research project that explored the experience of teenagers and young adults living with #Duchenne as they transition from pediatric care to adult care. Learn more about the study and its impact: bit.ly/3T1rXJ1